1
|
Valenzuela-Vázquez L, Nuñez-Enriquez JC, Sánchez-Herrera J, Medina-Sanson A, Pérez-Saldivar ML, Jiménez-Hernández E, Martiín-Trejo JA, Del Campo-Martínez MDLÁ, Flores-Lujano J, Amador-Sánchez R, Mora-Ríos FG, Peñaloza-González JG, Duarte-Rodríguez DA, Torres-Nava JR, Espinosa-Elizondo RM, Cortés-Herrera B, Flores-Villegas LV, Merino-Pasaye LE, Almeida-Hernández C, Ramírez-Colorado R, Solís-Labastida KA, Medrano-López F, Pérez-Gómez JA, Velázquez-Aviña MM, Martínez-Ríos A, Aguilar-De los Santos A, Santillán-Juárez JD, Gurrola-Silva A, García-Velázquez AJ, Mata-Rocha M, Hernández-Echáurregui GA, Sepúlveda-Robles OA, Rosas-Vargas H, Mancilla-Herrera I, Jimenez-Morales S, Hidalgo-Miranda A, Martinez-Duncker I, Waight JD, Hance KW, Madauss KP, Mejía-Aranguré JM, Cruz-Munoz ME. NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia. Front Oncol 2022; 12:1023510. [PMID: 36419901 PMCID: PMC9677112 DOI: 10.3389/fonc.2022.1023510] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 10/17/2022] [Indexed: 11/09/2022] Open
Abstract
NK cells have unique attributes to react towards cells undergoing malignant transformation or viral infection. This reactivity is regulated by activating or inhibitory germline encoded receptors. An impaired NK cell function may result from an aberrant expression of such receptors, a condition often seen in patients with hematological cancers. Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer worldwide and NK cells have emerged as crucial targets for developing immunotherapies. However, there are important gaps concerning the phenotype and behavior of NK cells during emergence of ALL. In this study we analyze the phenotype and function of NK cells from peripheral blood in pediatric patients with ALL at diagnosis. Our results showed that NK cells exhibited an altered phenotype highlighted by a significant reduction in the overall expression and percent representation of activating receptors compared to age-matched controls. No significant differences were found for the expression of inhibitory receptors. Moreover, NK cells with a concurrent reduced expression in various activating receptors, was the dominant phenotype among patients. An alteration in the relative frequencies of NK cells expressing NKG2A and CD57 within the mature NK cell pool was also observed. In addition, NK cells from patients displayed a significant reduction in the ability to sustain antibody-dependent cellular cytotoxicity (ADCC). Finally, an aberrant expression of activating receptors is associated with the phenomenon of leukemia during childhood.
Collapse
Affiliation(s)
- Lucero Valenzuela-Vázquez
- Facultad de Medicina, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
- Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
| | - Juan Carlos Nuñez-Enriquez
- Unidad de Investigación Médica en Epidemiología Clínica, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Jacqueline Sánchez-Herrera
- Facultad de Medicina, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
- Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
| | - Aurora Medina-Sanson
- Servicio de Oncología Pediátrica, Hospital Infantil de México, “Dr. Federico Gómez Sántos”, Secretaria de Salud, Ciudad de México, Mexico
| | - María Luisa Pérez-Saldivar
- Unidad de Investigación Médica en Epidemiología Clínica, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Elva Jiménez-Hernández
- Servicio de Hematología Pediátrica, Hospital General “Gaudencio González Garza”, Centro Médico Nacional (CMN) “La Raza”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Jorge Alfonso Martiín-Trejo
- Servicio de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - María de Los Ángeles Del Campo-Martínez
- Servicio de Hematología Pediátrica, Hospital General “Gaudencio González Garza”, Centro Médico Nacional (CMN) “La Raza”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Janet Flores-Lujano
- Unidad de Investigación Médica en Epidemiología Clínica, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Raquel Amador-Sánchez
- Hospital General Regional No. 1 “Carlos McGregor Sánchez Navarro”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Félix Gustavo Mora-Ríos
- Departamento de Hematología, Hospital General Regional Ignacio Zaragoza del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
| | | | - David Aldebarán Duarte-Rodríguez
- Unidad de Investigación Médica en Epidemiología Clínica, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - José Refugio Torres-Nava
- Servicio de Oncología, Hospital Pediátrico de Moctezuma, Secretaría de Salud de la Ciudad de México (CDMX), Mexico City, Mexico
| | | | - Beatriz Cortés-Herrera
- Servicio de Hematología Pediátrica, Hospital General de México, Secretaria de Salud (SS), Mexico City, Mexico
| | - Luz Victoria Flores-Villegas
- Servicio de Hematología Pediátrica, Centro Médico Nacional (CMN) “20 de Noviembre”, Instituto de Seguridad Social al Servicio de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
| | - Laura Elizabeth Merino-Pasaye
- Servicio de Hematología Pediátrica, Centro Médico Nacional (CMN) “20 de Noviembre”, Instituto de Seguridad Social al Servicio de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
| | - Carolina Almeida-Hernández
- Hospital General de Ecatepec “Las Américas”, Instituto de Salud del Estado de México (ISEM), Mexico City, Mexico
| | - Rosario Ramírez-Colorado
- Hospital Pediátrico La Villa, Secretaría de Salud de la Ciudad de México (SSCDMX), Mexico City, Mexico
| | - Karina Anastacia Solís-Labastida
- Servicio de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Francisco Medrano-López
- Hospital General Regional (HGR) No. 72 “Dr. Vicente Santos Guajardo”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Jessica Arleet Pérez-Gómez
- Hospital General Regional (HGR) No. 72 “Dr. Vicente Santos Guajardo”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | | | - Annel Martínez-Ríos
- Departamento de Hematología, Hospital General Regional Ignacio Zaragoza del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
| | | | - Jessica Denisse Santillán-Juárez
- Servicio de Hemato-oncología Pediátrica, Hospital Regional No. 1° de Octubre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
| | - Alma Gurrola-Silva
- Hospital Regional Tipo B de Alta Especialidad Bicentenario de la Independencia, Instituto de Seguridad Social al Servicio de los Trabajadores del Estado, Mexico City, Mexico
| | - Alejandra Jimena García-Velázquez
- Servicio de Hemato-oncología Pediátrica, Hospital Regional No. 1° de Octubre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
| | - Minerva Mata-Rocha
- Unidad de Investigación Médica en Epidemiología Clínica, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | | | - Omar Alejandro Sepúlveda-Robles
- Unidad de Investigación Médica en Genética Humana, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Haydeé Rosas-Vargas
- Unidad de Investigación Médica en Genética Humana, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Ismael Mancilla-Herrera
- Departamento de Infectología e Inmunología, Instituto Nacional de Perinatología, Mexico City, Mexico
| | - Silvia Jimenez-Morales
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico
| | - Alfredo Hidalgo-Miranda
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico
| | - Ivan Martinez-Duncker
- Centro de Investigación en Dinámica Celular, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
| | | | | | | | - Juan Manuel Mejía-Aranguré
- Unidad de Investigación Médica en Genética Humana, Unidad Médica de Alta Especialidad (UMAE) Hospital de Pediatría, Centro Médico Nacional (CMN) “Siglo XXI”, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico
- Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico
- *Correspondence: Juan Manuel Mejía-Aranguré, ; Mario Ernesto Cruz-Munoz,
| | - Mario Ernesto Cruz-Munoz
- Facultad de Medicina, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
- *Correspondence: Juan Manuel Mejía-Aranguré, ; Mario Ernesto Cruz-Munoz,
| |
Collapse
|
2
|
Gutierrez-Guerrero A, Mancilla-Herrera I, Maravillas-Montero JL, Martinez-Duncker I, Veillette A, Cruz-Munoz ME. SLAMF7 selectively favors degranulation to promote cytotoxicity in human NK cells. Eur J Immunol 2021; 52:62-74. [PMID: 34693521 DOI: 10.1002/eji.202149406] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 09/01/2021] [Accepted: 10/20/2021] [Indexed: 01/08/2023]
Abstract
NK cells play an important role in immunity by recognizing and eliminating cells undergoing infection or malignant transformation. This role is dependent on the ability of NK cells to lyse targets cells in a perforin-dependent mechanism and by secreting inflammatory cytokines. Both effector functions are controlled by several cell surface receptors. The Signaling Lymphocyte Activation Molecule (SLAM) family of receptors plays an essential role in regulating NK cell activation. Several studies have demonstrated that SLAMF7 regulates NK cell activation. However, the molecular and cellular mechanisms by which SLAMF7 influences NK effector functions are unknown. Here, we present evidence that physiological ligation of SLAMF7 in human NK cells enhances the lysis of target cells expressing SLAMF7. This effect was dependent on the ability of SLAMF7 to promote NK cell degranulation rather than cytotoxic granule polarization or cell adhesion. Moreover, SLAMF7-dependent NK cell degranulation was predominantly dependent on PLC-γ when compared to PI3K. These data provide novel information on the cellular mechanism by which SLAMF7 regulates human NK cell activation. Finally, this study supports a model for NK cell activation where activated receptors contribute by regulating specific discrete cellular events rather than multiple cellular processes.
Collapse
Affiliation(s)
- Arturo Gutierrez-Guerrero
- Facultad de Medicina, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, México.,Instituto de Investigación en Ciencias Básicas y Aplicadas, Mexico City, México
| | | | - Jose L Maravillas-Montero
- Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Mexico City, México.,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México
| | - Ivan Martinez-Duncker
- Centro de Investigación en Dinámica celular, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, México
| | - Andre Veillette
- Institute de Recherches Cliniques de Montréal (IRCM), Montréal, Québec, Canada
| | - Mario E Cruz-Munoz
- Facultad de Medicina, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, México
| |
Collapse
|
3
|
Lugo-Reyes SO, Pastor N, González-Serrano E, Yamazaki-Nakashimada MA, Scheffler-Mendoza S, Berron-Ruiz L, Wakida G, Nuñez-Nuñez ME, Macias-Robles AP, Staines-Boone AT, Venegas-Montoya E, Alaez-Verson C, Molina-Garay C, Flores-Lagunes LL, Carrillo-Sanchez K, Niemela J, Rosenzweig SD, Gaytan P, Yañez JA, Martinez-Duncker I, Notarangelo LD, Espinosa-Padilla S, Cruz-Munoz ME. Clinical Manifestations, Mutational Analysis, and Immunological Phenotype in Patients with RAG1/2 Mutations: First Cases Series from Mexico and Description of Two Novel Mutations. J Clin Immunol 2021; 41:1291-1302. [PMID: 33954879 DOI: 10.1007/s10875-021-01052-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 04/20/2021] [Indexed: 11/25/2022]
Abstract
Mutations in recombinase activating genes 1 and 2 (RAG1/2) result in human severe combined immunodeficiency (SCID). The products of these genes are essential for V(D)J rearrangement of the antigen receptors during lymphocyte development. Mutations resulting in null-recombination activity in RAG1 or RAG2 are associated with the most severe clinical and immunological phenotypes, whereas patients with hypomorphic mutations may develop leaky SCID, including Omenn syndrome (OS). A group of previously unrecognized clinical phenotypes associated with granulomata and/or autoimmunity have been described as a consequence of hypomorphic mutations. Here, we present six patients from unrelated families with missense variants in RAG1 or RAG2. Phenotypes observed in these patients ranged from OS to severe mycobacterial infections and granulomatous disease. Moreover, we report the first evidence of two variants that had not been associated with immunodeficiency. This study represents the first case series of RAG1- or RAG2-deficient patients from Mexico and Latin America.
Collapse
Affiliation(s)
| | - Nina Pastor
- Centro de Investigación en Dinámica Celular, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico
| | | | | | | | - Laura Berron-Ruiz
- Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico
| | - Guillermo Wakida
- Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico
| | | | | | | | - Edna Venegas-Montoya
- Unidad Médica de Alta Especialidad 25, Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | | | | | | | | | - Julie Niemela
- Laboratory of Clinical Immunology and Microbiology, National Institute of Health, Mexico City, Mexico
| | - Sergio D Rosenzweig
- Laboratory of Clinical Immunology and Microbiology, National Institute of Health, Mexico City, Mexico
| | - Paul Gaytan
- Instituto de Biotecnología, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - Jorge A Yañez
- Instituto de Biotecnología, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - Ivan Martinez-Duncker
- Centro de Investigación en Dinámica Celular, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico
| | - Luigi D Notarangelo
- Laboratory of Clinical Immunology and Microbiology, National Institute of Health, Mexico City, Mexico
| | - Sara Espinosa-Padilla
- Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico.
| | | |
Collapse
|
4
|
Papazoglu G, Ruiz SS, Salinas R, Pereira M, Cubilla M, Pesaola F, Ghione S, Ramadán N, Martinez-Duncker I, Asteggiano C. Platelet Membrane Glycoprofiling in a PMM2-CDG Patient. J inborn errors metab screen 2021. [DOI: 10.1590/2326-4594-jiems-2020-0030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- G.M. Papazoglu
- Universidad Nacional de Córdoba, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina
| | - S.M. Silvera Ruiz
- Universidad Nacional de Córdoba, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina; Universidad Nacional de Córdoba, Argentina
| | - R. Salinas
- Universidad Autónoma del Estado de Morelos, México
| | | | - M.A. Cubilla
- Universidad Nacional de Córdoba, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina
| | - F. Pesaola
- Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina; Hospital de Niños de la Sma, Argentina
| | | | - N. Ramadán
- Fundación para el Progreso de la Medicina, Argentina
| | | | - C.G. Asteggiano
- Universidad Nacional de Córdoba, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina; Universidad Católica de Córdoba, Argentina
| |
Collapse
|
5
|
Llamas-Guillén BA, Pastor N, López-Herrera G, González-Serrano ME, Valenzuela-Vázquez L, Bravo-Adame ME, Villanueva-Cabello TM, Gaytán P, Yañez J, Martinez-Duncker I, Ruiz-Fernández M, Veillette A, Espinosa-Padilla SE, Cruz-Munoz ME. Two novel mutations in ZAP70 gene that result in human immunodeficiency. Clin Immunol 2017; 183:278-284. [PMID: 28912049 DOI: 10.1016/j.clim.2017.09.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 03/23/2017] [Accepted: 09/09/2017] [Indexed: 11/28/2022]
Affiliation(s)
| | - Nina Pastor
- Cell Dynamics Research Center-IICBA, Autonomous University of Morelos State, Mexico
| | | | | | | | | | | | - Paul Gaytán
- Biotechnology Institute, Autonomous National University of México, Mexico
| | - Jorge Yañez
- Biotechnology Institute, Autonomous National University of México, Mexico
| | | | | | | | | | - Mario Ernesto Cruz-Munoz
- School of Medicine, Autonomous University of Morelos State, Mexico; Diagnostic and Molecular Medicine Unit "Dr. Ruy Pérez Tamayo", Morelos Children Hospital, Mexico.
| |
Collapse
|
6
|
Chaumet-Riffaud P, Martinez-Duncker I, Marty AL, Richard C, Prigent A, Moati F, Sarda-Mantel L, Scherman D, Bessodes M, Mignet N. Synthesis and Application of Lactosylated, 99mTc Chelating Albumin for Measurement of Liver Function. Bioconjug Chem 2010; 21:589-96. [DOI: 10.1021/bc900275f] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Philippe Chaumet-Riffaud
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| | - Ivan Martinez-Duncker
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| | - Anne-Laure Marty
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| | - Cyrille Richard
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| | - Alain Prigent
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| | - Frederic Moati
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| | - Laure Sarda-Mantel
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| | - Daniel Scherman
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| | - Michel Bessodes
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| | - Nathalie Mignet
- Université Paris-Sud 11, EA4046, Kremlin-Bicêtre, F-94275, AP-HP, CHU de Bicêtre, Le Kremlin-Bicêtre, F-94275, Unité de Pharmacologie Chimique et Génétique, U640 INSERM, UMR8151 CNRS, Université Paris Descartes, Paris, France, F-75006, Université Paris 7, U733 INSERM, CRB3, Faculté Xavier Bichat, Paris, France, AP-HP, Hôpital Bichat, Paris, F-75018, and Faculty of Science, Morelos State Autonomous University, Cuernavaca, Mexico
| |
Collapse
|
7
|
Martinez-Duncker I, Dupré T, Piller V, Piller F, Candelier JJ, Trichet C, Tchernia G, Oriol R, Mollicone R. Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter. Blood 2004; 105:2671-6. [PMID: 15576474 DOI: 10.1182/blood-2004-09-3509] [Citation(s) in RCA: 124] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We have identified a homozygous G>A substitution in the donor splice site of intron 6 (IVS6 + 1G>A) of the cytidine monophosphate (CMP)-sialic acid transporter gene of Lec2 cells as the mutation responsible for their asialo phenotype. These cells were used in complementation studies to test the activity of the 2 CMP-sialic acid transporter cDNA alleles of a patient devoid of sialyl-Le(x) expression on polymorphonuclear cells. No complementation was obtained with either of the 2 patient alleles, whereas full restoration of the sialylated phenotype was obtained in the Lec2 cells transfected with the corresponding human wild-type transcript. The inactivation of one patient allele by a double microdeletion inducing a premature stop codon at position 327 and a splice mutation of the other allele inducing a 130-base pair (bp) deletion and a premature stop codon at position 684 are proposed to be the causal defects of this disease. A 4-base insertion in intron 6 was found in the mother and is proposed to be responsible for the splice mutation. We conclude that this defect is a new type of congenital disorder of glycosylation (CDG) of type IIf affecting the transport of CMP-sialic acid into the Golgi apparatus.
Collapse
Affiliation(s)
- Ivan Martinez-Duncker
- Inistitut National de la Santé et de la Recherche Médicale (INSERM U504), Groupement de Recherche (GDR), Centre National de la Recherche Scientifque (CNRS) 2590, University of Paris Sud XI, Villejuif 94807, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Martinez-Duncker I, Mollicone R, Candelier JJ, Breton C, Oriol R. A new superfamily of protein-O-fucosyltransferases, alpha2-fucosyltransferases, and alpha6-fucosyltransferases: phylogeny and identification of conserved peptide motifs. Glycobiology 2003; 13:1C-5C. [PMID: 12966037 DOI: 10.1093/glycob/cwg113] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The presence of three conserved peptide motifs shared by alpha2-fucosyltransferases, alpha6-fucosyltransferases, the protein-O-fucosyltransferase family 1 (POFUT1) and a newly identified protein-O-fucosyltransferase family 2 (POFUT2), together with evidence that the present genes encoding for these enzymes have originated from a common ancestor by duplication and divergent evolution, suggests that they constitute a new superfamily of fucosyltransferases.
Collapse
Affiliation(s)
- Ivan Martinez-Duncker
- Unité de Glycobiologie et Signalisation Cellulaire, INSERM U504, GDR CNRS 2590, Université de Paris Sud XI, 16 Ave Paul Vaillant-Couturier, 94807 Villejuif Cedex France
| | | | | | | | | |
Collapse
|
9
|
Martinez-Duncker I, Michalski JC, Bauvy C, Candelier JJ, Mennesson B, Codogno P, Oriol R, Mollicone R. Activity and tissue distribution of splice variants of alpha6-fucosyltransferase in human embryogenesis. Glycobiology 2003; 14:13-25. [PMID: 14514715 DOI: 10.1093/glycob/cwh006] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The product of the FUT8 gene transfers an alpha1-6 fucose on the innermost N-acetylglucosamine of the chitobiose core of N-glycans. Northern blot analysis shows four main transcripts of 3.0, 3.3, 3.9, and 4.2 kb in the embryo. The larger forms around 4-kb decrease in fetus and adult. Fourteen embryo transcripts of FUT8 were cloned. Twelve exons comprising two new 5'untranslated-exons (A and B) and two new 3'UT-ends (L1 and L2) and the complete genomic organization of the FUT8 gene (330 kb) are described. Transcripts starting with the 5'UT-exon A are always associated with exons C and D. Exon B initiates another series of transcripts associated to exon C and D or directly to exon D. A third series of transcripts starts at exon C. The data suggest an expression of FUT8 regulated by three different promoters, starting transcription in exons A, B, or C. The A or C series are better expressed than the B series. After transfection with these cDNA constructs the transcripts with 5'UT-exons A or C have higher expression of FUT8 transcripts and higher alpha6-fucosyltransferase activity, whereas the activity of the B series is about two-thirds lower for both parameters, suggesting that exon B reduces the expression of the transcripts.
Collapse
Affiliation(s)
- Ivan Martinez-Duncker
- Unité de Glycobiologie et Signalisation Cellulaire, INSERM U504, IFR 89, GDR CNRS 2590, Université de Paris Sud XI, 16 Ave Paul Vaillant-Couturier, 94807 Villejuif France
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Nucleotide sugar transporters (NST) establish the functional link of membrane transport between the nucleotide sugars synthesized in the cytoplasm and nucleus, and the glycosylation processes that take place in the endoplasmic reticulum (ER) and Golgi apparatus. The aim of the present work was to perform a phylogenetic analysis of 87 bank annotated protein sequences comprising all the NST so far characterized and their homologues retrieved by BLAST searches, as well as the closely related triose-phosphate translocator (TPT) plant family. NST were classified in three comprehensive families by linking them to the available experimental data. This enabled us to point out both the possible ER subcellular targeting of these transporters mediated by the dy-lysine motif and the substrate recognition mechanisms specific to each family as well as an important acceptor site motif, establishing the role of evolution in the functional properties of each NST family.
Collapse
Affiliation(s)
- Ivan Martinez-Duncker
- Inserm U504 Glycobiologie et signalisation cellulaire, Université de Paris Sud XI, 16, avenue Paul-Vaillant-Couturier, 94807 Villejuif, France.
| | | | | | | |
Collapse
|
11
|
Oriol R, Martinez-Duncker I, Chantret I, Mollicone R, Codogno P. Common origin and evolution of glycosyltransferases using Dol-P-monosaccharides as donor substrate. Mol Biol Evol 2002; 19:1451-63. [PMID: 12200473 DOI: 10.1093/oxfordjournals.molbev.a004208] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
On the basis of the analysis of 64 glycosyltransferases from 14 species we propose that several successive duplications of a common ancestral gene, followed by divergent evolution, have generated the mannosyltransferases and the glucosyltransferases involved in asparagine-linked glycosylation (ALG) and phosphatidyl-inositol glycan anchor (PIG or GPI), which use lipid-related donor and acceptor substrates. Long and short conserved peptide motifs were found in all enzymes. Conserved and identical amino acid positions were found for the alpha 2/6- and the alpha 3/4-mannosyltransferases and for the alpha 2/3-glucosyltransferases, suggesting unique ancestors for these three superfamilies. The three members of the alpha 2-mannosyltransferase family (ALG9, PIG-B, and SMP3) and the two members of the alpha 3-glucosyltransferase family (ALG6 and ALG8) shared 11 and 30 identical amino acid positions, respectively, suggesting that these enzymes have also originated by duplication and divergent evolution. This model predicts a common genetic origin for ALG and PIG enzymes using dolichyl-phospho-monosaccharide (Dol-P-monosaccharide) donors, which might be related to similar spatial orientation of the hydroxyl acceptors. On the basis of the multiple sequence analysis and the prediction of transmembrane topology we propose that the endoplasmic reticulum glycosyltransferases using Dol-P-monosaccharides as donor substrate have a multispan transmembrane topology with a first large luminal conserved loop containing the long motif and a small cytosolic conserved loop containing the short motif, different from the classical type II glycosyltransferases, which are anchored in the Golgi by a single transmembrane domain.
Collapse
Affiliation(s)
- Rafael Oriol
- INSERM U504, University of Paris Sud XI, Villejuif, France.
| | | | | | | | | |
Collapse
|